Mapping of Incontinence Quality of Life (I-QOL) scores to Assessment of Quality of Life 8D (AQoL-8D) utilities in patients with idiopathic overactive bladder

Health and Quality of Life Outcomes

Jeffrey Richardson¹  Angelo Iezzi¹  Kwong Ng²  Jonathan T Tan⁴  Gang Chen³ 

[1] Centre for Health Economics, Monash University, Melbourne, Australia;Allergan Pty Ltd, Pasir Panjang, Singapore;Flinders Health Economics Group, School of Medicine, Flinders University, Adelaide, Australia;Allergan Pty Ltd, Level 4, 810 Pacific Highway. Gordon, Melbourne, NSW 217, Australia

关键词: Utility;    Cross-walk;    Mapping;    AQoL;    I-QOL;    HRQOL;    Overactive bladder;    Urinary incontinence;   

Others  :  1164530
DOI  :  10.1186/s12955-014-0133-0

 received in 2014-05-09, accepted in 2014-08-14,  发布年份 2014

【 摘 要 】

Background

The Incontinence Quality of Life (I-QOL) questionnaire is a commonly used and validated incontinence specific QOL instrument. The objective of this study is to develop an algorithm to map I-QOL to the Assessment of Quality of Life (AQoL) 8D utility instrument in patients with idiopathic overactive bladder (iOAB).

Methods

I-QOL and AQoL-8D scores were collected in a survey of 177 Australian adults with urinary incontinence due to iOAB. Three statistical methods were used for estimation, namely ordinary least squares (OLS) regression, the robust MM-estimator, and the generalised linear models (GLM). Each included a range of explanatory variables. Model performance was assessed using key goodness-of-fit measures in the validation dataset.

Results

The I-QOL total score and AQoL-8D utility scores were positively correlated (r?=?0.50, p?

Conclusions

The mapping algorithm developed in this study allows the derivation of AQoL-8D utilities from I-QOL scores. The algorithm allows the calculation of preference-based QOL scores for use in cost-utility analyses to assess the impact of interventions in urinary incontinence.

【 授权许可】

   
2014 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Nitti VW: The prevalence of urinary incontinence. Rev Urol 2001, 3(Suppl 1):S2.
• [2]Minassian VA, Drutz HP, Al-Badr A: Urinary incontinence as a worldwide problem. Int J Gynecol Obstet 2003, 82(3):327-338.
• [3]Aguzzi G, Simona B, Rosanna T: Systematic review of urinary incontinence and overactive bladder cost-of-illness studies. Open Pharmacoeconomics Health Econ J 2010, 2:11-24.
• [4]Hu T-W, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T: Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urol 2004, 63(3):461-465.
• [5]Frick AC, Huang AJ, Van Den Eeden SK, Knight SK, Creasman JM, Yang J: Mixed urinary incontinence: greater impact on quality of life. J Urol 2009, 182(2):596.
• [6]Abrams P, Cardozo L, Wein A, Khoury S: Incontinence: 4th International Consultation on Incontinence. Health Publications, Paris, France; 2009.
• [7]Charalambous S, Trantafylidis A: Impact of urinary incontinence on quality of life. Pelviperineol 2009, 28(2):51-53.
• [8]Hawthorne G: Measuring Incontinence in Australia. Commonwealth of Australia; 2006.
• [9]Stewart W, Van Rooyen J, Cundiff G, Abrams P, Herzog A, Corey R, Hunt T, Wein A: Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20(6):327-336.
• [10]Brazier J, Ratcliffe J, Salomon J, Tsuchiya A: Measuring and Valuing Health Benefits for Economic Evaluation. Oxford University Press Inc, New York; 2007.
• [11]Brazier JE, Yang Y, Tsuchiya A, Rowen DL: A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 2010, 11(2):215-25.
• [12]Finkelstein MM, Skelly J, Kaczorowski J, Swanson G: Incontinence Quality of Life Instrument in a survey of primary care physicians. J Fam Pract 2002, 51(11):952.
• [13]McCallum J, Millar L, Dong T, Burston L: National Continence Management Strategy 0 Independent Evaluation Advisor Final Report: Phases 1 and 2. Commonwealth of Australia; 2006.
• [14]Oh SJ, Ku JH: Is a generic quality of life instrument helpful for evaluating women with urinary incontinence? Qual Life Res 2006, 15(3):493-501.
• [15]Jimenez-Cidre M, Ng-Mak D, Sahai A, Degboe A, Smoth C, Tsai K, Herschorn S: Assessment of characteristics, treatment-seeking behavior, and healthcare utilization in an international cohort of subjects with overactive bladder.Curr Med Res Opin 2014. In press.
• [16]Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DE: Quality of life of persons with urinary incontinence: Development of a new measure. Urol 1996, 47(1):67-71.
• [17]Patrick DL, Martin ML, Bushnell DM, Yalcin I, Wagner TH, Buesching DP: Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). Urol 1999, 53(1):71-76.
• [18]Bushnell D, Martin M, Summers K, Svihra J, Lionis C, Patrick D: Quality of Life of Women with Urinary Incontinence: Cross-cultural Performance of 15 Language Versions of the I-QOL. Qual Life Res 2005, 14(8):1901-1913.
• [19]Matza L, Brewster-Jordan J, Zyczynski T, Bavendam T: An updated review of quality-of-life questionnaires for urinary incontinence and overactive bladder: Which ones to use and why. Curr Bladder Dysfunct Rep 2006, 1(2):71-80.
• [20]Richardson J, Sinha K, Iezzi A, Khan MA: Modelling the utility of health states with the Assessment of Quality of Life (AQoL) 8D instrument: overview and utility scoring algorithm. In Research Paper 63, Center for Health Economics. Monash University, Victoria, Australia; 2011.
• [21]Richardson J, Iezzi A, Khan MA, Maxwell A: Validity and reliability of the Assessment of Quality of Life (AQoL-8D) multi attribute utility instrument. Patient 2013, 7(1):85-96.
• [22]Richardson J, Iezzi A, Khan MA, Maxwell A: Cross-national comparison of twelve quality of life instruments: MIC Paper 2 Australia. In Research Paper 78, Center for Health Economics. Monash University, Victoria, Australia; 2012.
• [23]Mortimer D, Segal L: Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decision Making 2008, 28(1):66-89.
• [24]Rabe-Hesketh S, Everitt B: A Handbook of Statistical Analyses Using Stata (Fourth Edition). Chapman & Hall/CRC, Boca Raton, FL; 2007.
• [25]Yohai VJ: High breakdown-point and high efficiency robust estimates for regression. Ann Stat 1987, 15(2):642-56.
• [26]Chen G, Stevens K, Rowen D, Ratcliffe J: From KIDSCREEN-10 to CHU9D: creating a unique mapping algorithm for application in economic evaluation. Health Qual Life Out 2014, 12:134. BioMed Central Full Text
• [27]Fox J: Applied Regression Analysis and Generalized Linear Models (Second Edition). SAGE Publications, Thousand Oaks, CA; 2008.
• [28]Cameron AC, Trivedi PK: Microeconometrics: Methods and Applications. Cambridge University Press, New York; 2005.
• [29]Kay S, Tolley K, Colayco D, Khalaf K, Anderson P, Globe D: Mapping EQ-5D utility scores from the Incontinence Quality of Life Questionnaire among patients with neurogenic and idiopathic overactive bladder. Value Health 2013, 16(2):394-402.
• [30]Kaambwa B, Billingham L, Bryan S: Mapping utility scores from the Barthel index. Eur J Health Econ 2013, 14(2):231-41.
• [31]Starkie HJ, Briggs AH, Chambers MG, Jones P: Predicting EQ-5D Values Using the SGRQ. Value Health 2011, 14(2):354-60.
• [32]Versteegh M, Rowen D, Brazier J, Stolk E: Mapping onto Eq-5 D for patients in poor health. Health Qual Life Out 2010, 8(1):141. BioMed Central Full Text
• [33]Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C: OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013, 64(2):249-56.
• [34]Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C: OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013, 89(6):2186-93.